Paper on Societal Value of COVID-19 Vaccines, Coauthored by Analysis Group Researchers, Earns Top-5 Ranking from the Journal of Medical Economics

March 3, 2023

The Journal of Medical Economics (JME) has announced its top-5 list of “high-impact” papers for 2022, including a study titled “The societal economic value of COVID-19 vaccines in the United States” that was coauthored by Analysis Group Managing Principals Noam Kirson and Patrick Lefebvre, Vice President Elyse Swallow, Manager Jessica Lu, and Senior Analysts Josie Maynard and Yashna Shivdasani. JME notes that its annual list is based on the blending of an “objective metric (number of views) with our own subjective appraisal of articles that we found remarkable.” 

For this study, the researchers developed a population-based economic model to estimate the total societal value generated from COVID-19 vaccines by avoiding COVID-19 infections as well as resuming social and economic activity more quickly. They separately estimated the value generated from life-years saved, health care costs avoided, quality of life gained, and US gross domestic product (GDP) gained under a range of plausible assumptions.

Dr. Kirson, Ms. Swallow, and Vice President Debbie Goldschmidt also were recognized by the Journal of Managed Care & Specialty Pharmacy for their work in this area for the separate study, “Direct health care costs associated with COVID-19 in the United States.”

Analysis Group congratulates the authors on their accomplishments.

View the JME’s top-5 list here